Videos

Want to analyze biotech clinical study results like a pro? Download our free plain-English guide for non-stats experts:

“Interpreting efficacy findings in biotech clinical trials”

 

Teaching videos — new

Our first set of free teaching videos is live! Check out these 4 short episodes on Kaplan-Meier curves and time-to-event studies, including basic features, summary stats, the graphs themselves, and “red flags.”

  1. Introduction (8:51)

2. Summary stats (6:54)

3. Graphs (10:32)

4. Red flags (8:44)

Want to get notified when we publish new videos on biotech clinical trials, financial modeling, and related topics? Sign up for our email list for updates!

Webinars and Q&A sessions

Want to invite Pharmagellan to be a guest for a live event, podcast, or video, moderate a panel, or run a virtual or in-person customized teaching session? Drop us an email.

Overview of challenges assessing biotech clinical trials, feat. Calliditas Therapeutics’ Tarpeyo (budenoside) for IgA nephropathy. (1h; Mar. 10, 2022)

Examples of analyzing completed and in-progress biotech trials: (1) ongoing Phase 3 study of BioArctic’s lecanemab in Alzheimer’s disease; (2) interim Phase 2 data from Vicore’s C21 in idiopathic pulmonary fibrosis; (3) early clinical data in NHL from BioInvent’s BI-1206. (1h; May 18, 2022)

Framework for assessing biotech clinical trial risk. (45 min; Feb. 16, 2022)

Wide-ranging Q&A on analyzing biotech studies, incl. P values, sample size calculations, Kaplan-Meier curves, and how to interpret positive and negative results. (1h; June 30, 2022)

Discussion of clinical trial execution risk with Ken Getz of Tufts University’s Center for the Study of Drug Discovery (1h; June 12, 2023)

Case study on biotech clinical trial risk, feat. NoNO Therapeutics’ nerinetide for acute ischemic stroke. (30 min; Feb. 23, 2022)

Q&A session on biotech financial modeling aimed at newbies through mid-level folks. (1h; Oct. 19, 2022)

Q&A with two biotech VCs, Rakhshita Dhar or Leaps by Bayer and Irena Melnikova of Pfizer Ventures (1h; Dec. 1, 2023)